- Investing Ideas
- Japanese Pharmaceuticals & Biotech Healthy high growth potential
Japanese Pharmaceuticals & Biotech Healthy high growth potential
Results
2
0 new
Analysts expect these companies to experience strong growth in earnings over the next 3 years. They also meet criteria around being in an acceptable financial position.
2 companies
Healios K.K
Market Cap: JP¥33.8b
Engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States.
4593
JP¥250.00
7D
1.6%
1Y
-40.9%
SanBio
Market Cap: JP¥83.8b
Engages in the development, production, and sale of regenerative cell medicines for the central nervous system in Japan and the United States.
4592
JP¥1,073.00
7D
16.8%
1Y
-50.6%